Investigators have demonstrated how molecular profiling tumors can be used to help predict treatment response and survival in patients with meningiomas, the most common type of primary brain tumor.
The majority of biomedical research efforts have been directed towards other kinds of brain tumors, particularly gliomas like glioblastoma. In the last 10 years or so, there's been a growing awareness that we should be doing something more for patients with these tumors.
The findings highlight the potential of using molecular data to improve clinical decision-making and outcomes for patients with meningiomas, according to Craig Horbinski, MD, PhD, director of Neuropathology in the Department of Pathology and a co-author of the study.
Only in the last decade, however, has more attention been focused on improving treatment strategies for patients with meningiomas, the management of which has not substantially changed in the last 50 years.
[
Collection
]
[
|
...
]